281 related articles for article (PubMed ID: 21632937)
1. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
Saavedra A; Giralt A; Rué L; Xifró X; Xu J; Ortega Z; Lucas JJ; Lombroso PJ; Alberch J; Pérez-Navarro E
J Neurosci; 2011 Jun; 31(22):8150-62. PubMed ID: 21632937
[TBL] [Abstract][Full Text] [Related]
2. Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.
Xifró X; Giralt A; Saavedra A; García-Martínez JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E
Neurobiol Dis; 2009 Dec; 36(3):461-9. PubMed ID: 19733666
[TBL] [Abstract][Full Text] [Related]
3. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
Gladding CM; Fan J; Zhang LY; Wang L; Xu J; Li EH; Lombroso PJ; Raymond LA
J Neurochem; 2014 Jul; 130(1):145-59. PubMed ID: 24588402
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.
Xifró X; García-Martínez JM; Del Toro D; Alberch J; Pérez-Navarro E
J Neurochem; 2008 Jun; 105(5):1596-612. PubMed ID: 18221365
[TBL] [Abstract][Full Text] [Related]
5. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.
Saavedra A; García-Martínez JM; Xifró X; Giralt A; Torres-Peraza JF; Canals JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E
Cell Death Differ; 2010 Feb; 17(2):324-35. PubMed ID: 19745829
[TBL] [Abstract][Full Text] [Related]
6. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
[TBL] [Abstract][Full Text] [Related]
7. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
[TBL] [Abstract][Full Text] [Related]
8. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
9. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.
Reiner A; Del Mar N; Deng YP; Meade CA; Sun Z; Goldowitz D
J Comp Neurol; 2007 Dec; 505(6):603-29. PubMed ID: 17948889
[TBL] [Abstract][Full Text] [Related]
10. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
[TBL] [Abstract][Full Text] [Related]
11. Early down-regulation of PKCδ as a pro-survival mechanism in Huntington's disease.
Rué L; Alcalá-Vida R; López-Soop G; Creus-Muncunill J; Alberch J; Pérez-Navarro E
Neuromolecular Med; 2014 Mar; 16(1):25-37. PubMed ID: 23896721
[TBL] [Abstract][Full Text] [Related]
12. Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model.
Gladding CM; Sepers MD; Xu J; Zhang LY; Milnerwood AJ; Lombroso PJ; Raymond LA
Hum Mol Genet; 2012 Sep; 21(17):3739-52. PubMed ID: 22523092
[TBL] [Abstract][Full Text] [Related]
13. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
Hansson O; Petersén A; Leist M; Nicotera P; Castilho RF; Brundin P
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8727-32. PubMed ID: 10411943
[TBL] [Abstract][Full Text] [Related]
15. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
[TBL] [Abstract][Full Text] [Related]
16. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
[TBL] [Abstract][Full Text] [Related]
17. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
Choudhury KR; Das S; Bhattacharyya NP
J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
[TBL] [Abstract][Full Text] [Related]
18. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
Farrar AM; Callahan JW; Abercrombie ED
Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
Petersén A; Chase K; Puschban Z; DiFiglia M; Brundin P; Aronin N
Exp Neurol; 2002 May; 175(1):297-300. PubMed ID: 12009780
[TBL] [Abstract][Full Text] [Related]
20. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.
Gratuze M; Noël A; Julien C; Cisbani G; Milot-Rousseau P; Morin F; Dickler M; Goupil C; Bezeau F; Poitras I; Bissonnette S; Whittington RA; Hébert SS; Cicchetti F; Parker JA; Samadi P; Planel E
Hum Mol Genet; 2015 Jan; 24(1):86-99. PubMed ID: 25205109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
